Re: Q3 Events updated
|
2
|
Resverlogix Corp.
|
Aug 11, 2017 03:09PM
|
Re: RVX's place in therapy - future prediction
|
2
|
Resverlogix Corp.
|
Mar 13, 2021 04:31PM
|
Re: Added a few more to the pile...
|
2
|
Resverlogix Corp.
|
Nov 09, 2017 11:59AM
|
Re: Additional Reports of Exempt Distribution
|
2
|
Zenith Epigenetics
|
Jul 24, 2023 05:11PM
|
Re: Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
|
2
|
Resverlogix Corp.
|
Sep 05, 2017 10:35AM
|
Re: Thoughts on ZCC
|
2
|
Zenith Epigenetics
|
Sep 10, 2021 01:34PM
|
Re: Reports of Exempt Distribution
|
2
|
Zenith Epigenetics
|
Feb 22, 2023 09:43AM
|
Re: Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada.
|
2
|
Zenith Epigenetics
|
Feb 11, 2019 01:27PM
|
Re: With so many events coming up.....
|
2
|
Resverlogix Corp.
|
Jul 07, 2015 12:58PM
|
Re: Zenith $1.00 per share and no mention of New CEO
|
2
|
Resverlogix Corp.
|
May 15, 2015 12:49PM
|
Re: Resverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events
|
2
|
Resverlogix Corp.
|
Apr 18, 2019 02:55PM
|
Re: NR: Resverlogix Highlights Key Accomplishments and 2018 Targets...
|
2
|
Resverlogix Corp.
|
Feb 08, 2018 07:03PM
|
Re: Voting reminder
|
2
|
Resverlogix Corp.
|
Jun 09, 2023 07:08AM
|
Re: A little movie foreshadowing humor while we wait
|
2
|
Resverlogix Corp.
|
Feb 18, 2017 01:45PM
|
Re: AstraZeneca heart drug fails in key stroke trial .
|
2
|
Resverlogix Corp.
|
Mar 23, 2016 05:52PM
|
Re: Thoughts on ZCC
|
2
|
Zenith Epigenetics
|
Sep 17, 2021 01:55PM
|
Another week and .......................
|
2
|
Resverlogix Corp.
|
Dec 08, 2023 10:39AM
|
Re: Trial Status
|
2
|
Resverlogix Corp.
|
Jul 22, 2021 08:20PM
|
Re: China Deal for Zenith?
|
2
|
Resverlogix Corp.
|
May 15, 2015 01:08PM
|
Re: A couple of things....
|
2
|
Resverlogix Corp.
|
Sep 23, 2017 05:01PM
|